本次权益分派股权登记日为：2026年2月11日，除权除息日为：2026年2月12日。 格隆汇2月4日丨达仁堂(600329.SH)公布2025年季度权益分派实施公告,本次利润分配以方案实施前的公 司总股本770,094,356股为基数，每股派发现金红利2.45元（含税），共计派发现金红利1,886,731,172.2 元。 ...

证券日报网讯 1月28日，达仁堂发布公告称，公司于2026年1月28日以通讯方式召开了2026年第一次董 事会会议，会议审议通过了聘任陈洪先生为公司常务副总经理的议案。 （文章来源：证券日报） ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《公司法》、《证券法》和《公司章程》的有关规定，公司于 2026 年 1 月 28 日以通讯方式召开了 2026 年第一次董事会会议，会议审议通 过了聘任陈洪先生为公司常务副总经理的议案。（简历请参见附件） 公司董事会提名委员会对此事项发表了相关意见：根据公司提名， 我们审阅了聘任陈洪先生为公司常务副总经理的相关事项，并对其个人 履历进行了审查。我们认为，公司对于该高级管理人员候选人的提名程 序符合《公司章程》的有关要求，该高级管理人员候选人具备任职资格， 我们同意聘任陈洪先生为公司常务副总经理的事项。 特此公告。 证券代码：600329 证券简称：达仁堂 编号：临 2026-001 号 津药达仁堂集团股份有限公司 关于公司聘任高级管理人员的公告 津药达仁堂集团股份有限公司董事会 2026 年 1 月 29 日 1 附件： 陈洪先生简历：男，1970 年 8 月出生，中国籍，南京医科大学医学 学士，长江商学院 EMBA 硕士。2011 年 4 月至 2025 年 6 月，历任 ...

Core Viewpoint - The A-share pharmaceutical sector has gained renewed investor interest due to the resurgence of COVID-19 cases in India, leading to fluctuations in the Chinese medicine ETF (560080) and notable stock performance among key companies in the sector [1][6]. Group 1: Market Performance - The Chinese medicine ETF (560080) experienced a nearly 2% decline on January 27, following a more than 1.4% increase the previous day, with trading volume surpassing 85 million yuan [1]. - Notable declines were observed in key stocks within the ETF, including Zhongsheng Pharmaceutical down over 7% and Yiling Pharmaceutical down over 5%, with several others also experiencing declines [3]. Group 2: Valuation Insights - The latest price-to-earnings ratio (PE TTM) for the index tracked by the Chinese medicine ETF (560080) is 24.57, indicating that the valuation is below 81.27% of the time since the index was published in May 2015, suggesting a favorable valuation opportunity [4]. Group 3: Company News - Zhongsheng Pharmaceutical announced a projected net profit of 260 million to 310 million yuan for 2025, marking a significant turnaround with an increase of 186.91% to 203.62% year-on-year [7]. - Yiling Pharmaceutical also forecasted a net profit of 1.2 billion to 1.3 billion yuan for 2025, indicating a key operational turning point [7]. - Kangyuan Pharmaceutical received approval for clinical trials of a new traditional Chinese medicine aimed at treating children's adenoid hypertrophy, marking a step forward in innovation [7]. Group 4: Industry Trends - The Chinese traditional medicine market is projected to exceed 700 billion yuan in 2024, driven by stable demand amid an aging population, although pricing volatility has been influenced by inventory adjustments and procurement policies [8]. - The industry is experiencing a consolidation trend, with leading companies capturing over half of the market revenue and profits, while ongoing policy focus on innovation and quality development is reshaping the competitive landscape [8].

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Loxoprofen Sodium Gel Patch, allowing for production and sales, which enhances its product line in orthopedic medications and competitive position in the market [1][4]. Group 1: Drug Registration and Details - The Drug Registration Certificate for Loxoprofen Sodium Gel Patch was approved by the National Medical Products Administration on January 23, 2026 [1]. - Loxoprofen Sodium Gel Patch is indicated for osteoarthritis, muscle pain, and swelling pain after injuries, with significant anti-inflammatory and analgesic effects [1]. - The active ingredient, Loxoprofen Sodium, is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting prostaglandin synthesis [1]. Group 2: Market Situation - As of the announcement date, 15 companies in China have obtained the Drug Registration Certificate for Loxoprofen Sodium Gel Patch, including listed companies such as Jiutian Pharmaceutical, Darentang, and China Resources Sanjiu [3]. - According to Moen Pharmaceutical data, the total hospital sales of Loxoprofen Sodium Gel Patch reached 1.349 billion yuan in the first three quarters of 2025, with retail sales in physical pharmacies amounting to 142 million yuan in the first half of 2025 [3]. Group 3: Impact on the Company - The approval of Loxoprofen Sodium Gel Patch enriches the company's product line for orthopedic diseases and enhances its competitiveness in the market, potentially improving overall profitability [4]. - The company has invested a total of 7.0366 million yuan in the drug project, including research and development and technology transfer [2]. - The company emphasizes the importance of drug research and development, maintaining strict quality control in the drug development, manufacturing, and sales processes [4].

Market Overview - The Chinese medicine sector experienced a decline of 0.3% on December 31, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3968.84, up 0.09%, while the Shenzhen Component Index closed at 13525.02, down 0.58% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - ST Ziling: closed at 4.35, up 2.84% with a trading volume of 476,800 shares and a turnover of 207 million yuan [1] - Guohan Pharmaceutical: closed at 11.21, up 2.66% with a trading volume of 48,400 shares and a turnover of 54.01 million yuan [1] - Major decliners included: - *ST Changyao: closed at 0.87, down 8.42% with a trading volume of 828,300 shares and a turnover of 73.23 million yuan [2] - ST Huluwa: closed at 7.62, down 4.63% with a trading volume of 176,200 shares and a turnover of 134 million yuan [2] Capital Flow - The Chinese medicine sector saw a net outflow of 399 million yuan from institutional investors, while retail investors contributed a net inflow of 376 million yuan [2] - The sector's capital flow details indicate: - Dong'e Ejiao had a net inflow of 27.6 million yuan from institutional investors, but a net outflow of 14.69 million yuan from speculative funds [3] - Guohan Pharmaceutical experienced a net inflow of 8.03 million yuan from institutional investors, but a net outflow of 9.69 million yuan from retail investors [3]

Core Viewpoint - Daren Tang's stock price has shown significant growth this year, with a 61.25% increase, reflecting strong market performance and investor interest [2]. Group 1: Stock Performance - As of December 25, Daren Tang's stock price increased by 2.06%, reaching 47.60 CNY per share, with a total market capitalization of 36.656 billion CNY [1]. - The stock has experienced a 2.30% increase over the last five trading days, a 4.41% increase over the last 20 days, and a 5.59% increase over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Daren Tang reported a revenue of 3.670 billion CNY, a year-on-year decrease of 34.59%, while the net profit attributable to shareholders was 2.152 billion CNY, showing a year-on-year increase of 167.73% [2]. - The company has distributed a total of 5.117 billion CNY in dividends since its A-share listing, with 2.834 billion CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of Daren Tang's shareholders increased to 58,600, up by 7.46% from the previous period, with an average of 9,675 circulating shares per shareholder, a decrease of 6.94% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 4.9954 million shares, an increase of 533,000 shares compared to the previous period [3].

Group 1 - A-shares and Hong Kong stocks experienced a significant rebound, with the Shanghai Composite Index rising by 1.19% and the Hang Seng Index increasing by 0.92% [1] - The largest medical ETF in the market (512170) and the only drug ETF (562050) both rose over 1%, indicating a broad recovery in the medical sector [1] - The medical ETF (512170) showed a strong technical signal with a "bullish engulfing" pattern, suggesting a potential trend reversal [1] Group 2 - The pharmaceutical sector in A-shares also saw a surge, with the drug ETF (562050) rising by 1.19%, driven by contributions from innovative and traditional Chinese medicine stocks [3] - The drug ETF (562050) has approximately 25% weight in traditional Chinese medicine, which helps mitigate the volatility of the overall pharmaceutical index [3] Group 3 - The Hong Kong innovation drug sector is showing signs of recovery, with the Hong Kong innovation drug ETF (520880) successfully closing in the green, attracting "bottom-fishing" funds [5] - The fund size of the Hong Kong innovation drug ETF (520880) reached a new high of 4.172 billion shares, reflecting strong investor interest [5] Group 4 - The A+H pharmaceutical sector has been in a correction phase for three months, and analysts suggest that this may be an opportune time for medium to long-term investments in pharmaceutical assets [8] - Recent positive developments in the pharmaceutical industry include overseas collaborations and increasing demand for CXO services, indicating a favorable outlook for the sector [9] Group 5 - The fund manager of the Hong Kong innovation drug ETF (520880) maintains a balanced allocation strategy, highlighting the potential for recovery in the innovative drug industry and related sectors [10] - New investment tools, such as the Hong Kong medical ETF (159137), are being launched to track the medical innovation theme, covering various core leaders in the medical field [7]

Group 1 - The "2025 China Digital Automotive Competition - Digital Ring Driving China Competition" commenced in Wuqing District, Tianjin, showcasing the integration of digital technology in automotive events [1] - The event has covered over 10,000 kilometers across 10 provincial-level administrative regions, presenting various challenges such as high-altitude conditions, mountainous roads, and diverse weather [1] - TCM (Traditional Chinese Medicine) company Tianyao Darentang provided health support for participants, offering customized health packages to address common travel-related discomforts [1][3] Group 2 - The competition highlights the technological strength of China's automotive industry while merging traditional Chinese medicine with modern events [3] - Each kilometer traveled represents a combination of technology and courage, emphasizing the importance of professional health support during extreme challenges [3] - The ongoing event continues to attract attention for its scenic routes and the challenges faced by participants, promising further excitement [3]

Group 1 - The third Tianjin Qihuang Forum and the first Guoyun Traditional Chinese Medicine Cultural Industry Innovation Development Summit opened on November 15, focusing on the theme of "inheritance, innovation, integration, and development" [1] - The event gathered over 200 participants, including academicians, masters of traditional Chinese medicine, scholars, industry experts, and representatives from the traditional Chinese medicine industry chain, promoting deep integration of traditional Chinese medicine and cultural industries [1][3] - The summit featured a three-dimensional model of "academic discussion + industry docking + cultural experience," aiming to inject new momentum into Tianjin's goal of becoming a leading domestic and internationally renowned city for traditional Chinese medicine [1] Group 2 - This year's forum uniquely combined the "Guoyun Traditional Chinese Medicine Cultural Industry Innovation Development Summit," focusing on innovation in the traditional Chinese medicine health industry and upgrading the industry chain, enhancing cross-industry integration and international dissemination [3] - A showcase of ten products, including medicinal food bread and special stamps, was held, with three products highlighted for promotion, attracting significant attention from attendees [3][5] - The forum included discussions on international pathways for promoting traditional Chinese culture, with a presentation by the Deputy Director of the Brand and Market Center of Tianjin Pharmaceutical Daren Tang Group, focusing on the brand's renewal and internationalization efforts [5][6] Group 3 - In a sub-forum on upgrading the traditional Chinese medicine industry chain, the Chief Information Officer of Tianjin Pharmaceutical Daren Tang Group presented on the company's digital transformation and AI strategies, showcasing the results of their AI practices and data innovation since the transformation [8][9]